MOTS-c 10mg Anti-Aging

Reconstitution protocols documented in the research literature recommend adding 1-2 ml of sterile bacteriostatic water (0.9% benzyl chloride) to a 10 mg MOTS-c vial, producing a solution at 5-10 mg per milliliter. This concentration facilitates standard experimental doses (5-15 mg) with a 29G 1ml insulin syringe. At 10 mg/ml, 1 ml contains 10 mg, allowing easy administration of doses of 5 mg (0.5 ml) or 10 mg (1 ml).

The pharmacokinetics of MOTS-c is characterized by a Tmax of 30-60 minutes after subcutaneous injection, a plasma half-life of approximately 2-3 hours (longer than simple peptides of same size, probably linked to hydrophobic structure and binding with plasma proteins), and a more prolonged biological duration of action reaching 24-48 hours via effects on AMPK signaling and induced transcriptional modifications. This duration of action allows administration 2-3 times per week in experimental protocols.

Experimental doses commonly reported in animal models are between 0.5 and 5 mg per kilogram body weight per administration. Reynolds 2021 used 15 mg/kg in aged mice over 8 weeks. Observational non-pharmacological human research protocols do not involve exogenous administration. Documented experimental doses in publications include 5-15 mg per subcutaneous injection in human subjects (approximately 0.07-0.2 mg/kg), 2-3 times per week over periods of 8-12 weeks.

Chronic schemes reported alternate active periods of 8-12 weeks with 2-4 week pauses to allow adaptive transcriptional response without saturation of AMPK pathways and without potential cellular desensitization. The administration window is generally morning due to the synergy observed with the circadian rhythm of the AMPK pathway, itself more active in the morning during post-overnight fasting period.

Association with physical exercise is documented in several preclinical studies as synergistic. MOTS-c administered before or after a resistance or endurance exercise session amplifies the observed metabolic effects, probably via convergence of AMPK, PGC-1alpha and myofibrillar protein synthesis pathways. Experimental protocols often combine MOTS-c plus structured exercise 3-5 times per week.

Combination with other mitochondrial or metabolic peptides is theoretically relevant. MOTS-c plus SS-31 covers two distinct mitochondrial aspects (retrograde signaling for MOTS-c, membrane integrity for SS-31). MOTS-c plus Humanin combines two peptide mitokines with complementary systemic actions (metabolic for MOTS-c, anti-apoptotic for Humanin). These combinations remain experimental without formal clinical validation.

Subcutaneous injection in abdominal fat, thigh or deltoid is the standard route. MOTS-c is not sensitive to food interference and can be injected on empty stomach or after meal without significant difference on biological activity. Preservation of injection site consistency over several weeks facilitates experimental reproducibility.

Before reconstitution, the lyophilized vial of MOTS-c 10mg must be stored between 2 and 8 degrees Celsius, in its original packaging, away from direct light and any heat source. Under these conditions, the lyophilizate stability is ensured for 24 to 36 months from the manufacturing date mentioned on the certificate of analysis. The stability of lyophilized MOTS-c is comparable to that of medium-sized linear peptides, without the presence of residues particularly sensitive to oxidation or photolysis.

Prolonged storage at ambient temperature (>25 degrees Celsius) must remain exceptional and not exceed 72 hours; beyond that, a risk of degradation and potency loss exists. Excessive heat (>40 degrees Celsius) causes accelerated hydrolysis of peptide bonds and irreversibly compromises the molecule's biological activity.

After reconstitution with sterile bacteriostatic water, the aqueous MOTS-c solution remains stable for approximately 30 days at 2-8 degrees Celsius. This duration is in the standard range of research peptides comparable to Ipamorelin, GHRP-6 and Hexarelin. Freezing at -20 degrees Celsius or less extends stability up to 4-6 months under optimal conditions. However, each freeze-thaw cycle partially degrades the molecule and must be avoided.

Best practice is to aliquot the reconstituted solution into portions corresponding to 2-3 weeks of experimental use (i.e. 4-6 doses of 10 mg each), then freeze the aliquots individually in sterile cryotubes. The thawed multi-dose vial is then used for a maximum of 30 days in refrigeration at 2-8 degrees Celsius.

Light protection is recommended but not critical for MOTS-c, sequence less photosensitive than peptides containing multiple tryptophan residues. The original opaque packaging or storage in a closed refrigerator drawer suffices in most configurations. Protection against intense mechanical agitation remains essential: never shake the vial violently during reconstitution. Gentle rotation between palms for 2-3 minutes suffices for complete lyophilizate dissolution.

Any solution presenting a color change (normally colorless and clear), a precipitate, or particles in suspension must be immediately discarded. Visual inspection before each sampling is a mandatory practice in research context. Atlas Lab provides detailed recommendations and certificates of analysis to ensure rigorous lot-by-lot experimental traceability. Traceability is particularly important for MOTS-c due to its relative novelty (discovered in 2015) and the sensitivity of metabolic study models to residual molecular contaminations that could interfere with the studied AMPK or mTOR pathways.